<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>InflaRx N.V. (IFRX) 週二宣佈了關於其在膿皰性壞死性皮膚病中使用 vilobelimab 的三期研究的最新進展，該研究在今年早些時候被終止，因為獨立數據監測委員會建議提前停止試驗，原因是無效。</p>
<p>最近公佈的深入數據分析顯示了該治療的有效性，特別是在潰瘍體積減少方面，這進一步支持了 C5a/C5aR 通路在某些中性粒細胞皮膚疾病中的潛在作用。</p>
<p>公司指出，兩個連續訪視中完全靶向潰瘍閉合的主要臨牀終點顯示，vilobelimab 相較於安慰劑的差異為 20.8% 對 16.7%。</p>
<p>與此同時，完全疾病緩解等關鍵次要終點顯示出 vilobelimab 相較於安慰劑的改善。</p>
<p>公司預計將與 FDA 召開會議，討論 vilobelimab 的潛在前進路徑。</p>
<p>在盤前交易時段，IFRX 在納斯達克下跌 3.93%，至 0.97 美元。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

IFRX

<p>InflaRx N.V. (IFRX) 宣佈了其針對膿皰性壞死性皮膚病的第三階段研究更新，該研究因無效而終止。深入分析顯示，vilobelimab 在潰瘍體積減少方面的療效顯著，閉合率為 20.8%，而安慰劑為 16.7%。關鍵的次要終點也支持 vilobelimab。公司計劃與 FDA 會面討論未來的步驟。在盤前交易中，IFRX 股價下跌 3.93%，至 0.97 美元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>InflaRx N.V. (IFRX), Tuesday announced updates regarding its Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this year after an Independent Data Monitoring Committee recommended the trial be stopped early due to futility.</p>
<div class="lb-trans"><p>InflaRx N.V. (IFRX) 週二宣佈了關於其在膿皰性壞死性皮膚病中使用 vilobelimab 的三期研究的最新進展，該研究在今年早些時候被終止，因為獨立數據監測委員會建議提前停止試驗，原因是無效。</p>
</div><p>The recently announced in-depth data analysis reveals the treatment's efficacy, particularly regarding ulcer volume reduction, which further supports the potential role of the C5a/C5aR pathway in certain neutrophilic skin diseases.</p>
<div class="lb-trans"><p>最近公佈的深入數據分析顯示了該治療的有效性，特別是在潰瘍體積減少方面，這進一步支持了 C5a/C5aR 通路在某些中性粒細胞皮膚疾病中的潛在作用。</p>
</div><p>The company noted that the primary clinical endpoint of complete target ulcer closure on two consecutive visits showed a difference in favor of vilobelimab over placebo of 20.8 percent versus 16.7 percent.</p>
<div class="lb-trans"><p>公司指出，兩個連續訪視中完全靶向潰瘍閉合的主要臨牀終點顯示，vilobelimab 相較於安慰劑的差異為 20.8% 對 16.7%。</p>
</div><p>Meanwhile, key secondary endpoints such as complete disease remission showed improvement in favor of vilobelimab over placebo.</p>
<div class="lb-trans"><p>與此同時，完全疾病緩解等關鍵次要終點顯示出 vilobelimab 相較於安慰劑的改善。</p>
</div><p>The company expects to have a meeting with the FDA to discuss a potential path forward for vilobelimab.</p>
<div class="lb-trans"><p>公司預計將與 FDA 召開會議，討論 vilobelimab 的潛在前進路徑。</p>
</div><p>In the pre-market hours, IFRX is moving down 3.93 percent, to $0.97 on the Nasdaq.</p>
<div class="lb-trans"><p>在盤前交易時段，IFRX 在納斯達克下跌 3.93%，至 0.97 美元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

InflaRx 關於 Vilobelimab 的深入分析，盤前股價下跌